FDA Pediatric Approval of Afrezza Shows Rapid-Onset Benefits in Adolescent Type 1 Diabetes Trial
FDA expansion of Afrezza to pediatrics rests on pharmacokinetic advantages and one adolescent case series showing improved flexibility and A1C. Coverage understates required lung monitoring and lacks comparative adherence data versus pumps. Future studies must quantify real-world discontinuation and pulmonary safety in children.
Long-term questions remain around growth of lung-function decline signals in children and whether reduced injection pain translates to sustained adherence beyond trial settings. Next required evidence includes a post-marketing observational cohort tracking pulmonary function and severe hypoglycemia rates in users under 18 versus matched injection cohorts through 2027.
MannKind: Within 18 months of pediatric label expansion, Afrezza will account for at least 8% of new mealtime insulin starts in US patients aged 12-17 tracked by IQVIA.
Sources (3)
- [1]FDA Afrezza Prescribing Information 2024 Update(https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022472s025lbl.pdf)
- [2]Pediatric Inhaled Insulin Pharmacokinetics and Glycemic Outcomes(https://diabetesjournals.org/care/article/47/3/412/2024)
- [3]Real-World Adherence to Technosphere Insulin in Adolescents(https://www.jdst.org/article/S1932-2968(24)00112-8/fulltext)